Both activating and resistance mutations in other oncogenes such as KRAS and BRAF [21–23] as well as inactivating mutations in the tumour suppressor gene TP53 [24–26] are also found in NSCLC patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.